Biocryst (BCRX) Falls After Company Left Out of CDC's Recommened Flu Drugs
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Join SI Premium – FREE
Shares Biocryst Pharmaceuticals (Nasdaq: BCRX) fell mid-day after the company's peramivir wasn't on an updated list of flu treatment guidelines released by the CDC.
The CDC is recommending treatment with Roche's oseltamivir (Tamiflu) or GlaxoSmithKline's (NYSE: GSK) zanamivir (Relenza) for all persons with suspected or confirmed influenza requiring hospitalization.
Shares of BCRX are down down 5.9% in late afternoon trading.
The CDC is recommending treatment with Roche's oseltamivir (Tamiflu) or GlaxoSmithKline's (NYSE: GSK) zanamivir (Relenza) for all persons with suspected or confirmed influenza requiring hospitalization.
Shares of BCRX are down down 5.9% in late afternoon trading.
You May Also Be Interested In
- SEC accuses ex-BofA senior banker Satsky of insider trading - Bloomberg
- DOJ, TikTok settle for $400m in children's privacy suit - Axios
- Anthropic hires Google chip veteran as it pushed into hardware - Bloomberg
Create E-mail Alert Related Categories
Insiders' Blog, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
